Qiagen Sees Brighter Reimbursement Outlook For Companion Diagnostics
This article was originally published in The Gray Sheet
Personalized health care remains an important growth driver for the diagnostics developer, which is juggling some 15 companion diagnostics projects. The reimbursement landscape for FDA-approved tests is improving, Qiagen says.
You may also be interested in...
Qiagen will co-develop and commercialize a companion diagnostic for AstraZeneca’s Iressa lung-cancer drug under an agreement between the firms. Ortho-Clinical Diagnostics will sell a test system for acute kidney injury. BD nabs 510(k)s for STD assays.
Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.